Skip to main content

Table 3 Predictors of new-onset AF for diabetic patients taking hypoglycemic agents after propensity score weighting

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

  Hazard ratio (95% CI); P value
Univariate Multivariate
DPP4i versus other hypoglycemic agents 0.65 (0.56–0.76); < 0.0001 0.69 (0.59–0.81); P < 0.0001
Age (years)
 < 65 1.00 (reference) 1.00 (reference)
 ≥ 65 5.76 (4.97–6.68); < 0.0001 4.75 (4.07–5.55); P < 0.0001
Female gender 0.87 (0.75–1.01); 0.0714  
Chronic lung disease 2.28 (1.46–3.56); 0.0003  
Chronic kidney disease 1.74 (1.37–2.21); < 0.0001  
Hypertension 2.64 (2.22–3.13); < 0.0001 1.74 (1.45–2.06); P < 0.0001
Ischemic heart disease 3.84 (2.88–5.13); < 0.0001 1.98 (1.48–2.66); P < 0.0001
  1. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1, PAOD peripheral arterial obstructive disease, TZD thiazolidinedione